{"id":"iv-dalbavancin","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalbavancin binds to the D-Ala-D-Ala terminus of peptidoglycan precursors in bacterial cell walls, preventing cross-linking and disrupting cell wall integrity. This leads to bacterial cell lysis and death. The drug has an extended half-life due to its lipophilic side chain, allowing for less frequent dosing compared to vancomycin.","oneSentence":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:26.185Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria"},{"name":"Staphylococcus aureus bacteremia including endocarditis"}]},"trialDetails":[{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05117398","phase":"PHASE3","title":"Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-23","conditions":"Catheter Bacteremia, Staphylococcus Aureus Infection","enrollment":406},{"nctId":"NCT04775953","phase":"PHASE2","title":"DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Staphylococcal Bacteraemia","enrollment":200},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":"Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections","enrollment":199},{"nctId":"NCT06266494","phase":"PHASE4","title":"Prevention and Treatment of Frostbite Infection With Antimicrobial Pharmacokinetic Analysis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-03-01","conditions":"Frostbite","enrollment":100},{"nctId":"NCT03982030","phase":"PHASE4","title":"Dalbavancin Outpatient Pilot","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-04","conditions":"Gram-Positive Bacterial Infections, Soft Tissue Infections","enrollment":""},{"nctId":"NCT03148756","phase":"PHASE2","title":"Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis","status":"TERMINATED","sponsor":"AbbVie","startDate":"2017-05-12","conditions":"Endocarditis, Bacteremia","enrollment":2},{"nctId":"NCT02940730","phase":"PHASE4","title":"Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-05-01","conditions":"Infectious Peritonitis","enrollment":10},{"nctId":"NCT02961764","phase":"PHASE4","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-11-29","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":313},{"nctId":"NCT03233438","phase":"PHASE4","title":"Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","status":"COMPLETED","sponsor":"Allergan","startDate":"2017-07-24","conditions":"Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection","enrollment":91},{"nctId":"NCT02685033","phase":"PHASE2","title":"Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2016-03-15","conditions":"Osteomyelitis","enrollment":80},{"nctId":"NCT02127970","phase":"PHASE3","title":"Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2014-04-18","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":698},{"nctId":"NCT03091439","phase":"PHASE2","title":"Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis","status":"TERMINATED","sponsor":"Allergan","startDate":"2017-05-15","conditions":"Osteomyelitis","enrollment":1},{"nctId":"NCT02344511","phase":"PHASE3","title":"Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis","status":"WITHDRAWN","sponsor":"Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)","startDate":"2016-03","conditions":"Osteomyelitis","enrollment":""},{"nctId":"NCT02269644","phase":"PHASE3","title":"A P3 Comparator Trial in Community Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2015-11","conditions":"Community Acquired Pneumonia","enrollment":""},{"nctId":"NCT01431339","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-07","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":739},{"nctId":"NCT01339091","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-03","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":573},{"nctId":"NCT00678106","phase":"PHASE1","title":"Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09","conditions":"Bacterial Infections","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IV Dalbavancin","genericName":"IV Dalbavancin","companyName":"Durata Therapeutics Inc., an affiliate of Allergan plc","companyId":"durata-therapeutics-inc-an-affiliate-of-allergan-plc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. Used for Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, Staphylococcus aureus bacteremia including endocarditis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}